FIELD: medicine, oncology, immunology.
SUBSTANCE: invention relates to antibodies directed on EGF-receptor (HER1) for designation to human, in particularly, for therapeutic using in tumors. Antibodies represent modified antibodies wherein their modification results to reduced tendency to induce immune response after their administration in human. In particular, invention relates to modification of anti-EGER antibody 425 in its different forms and their fragments that results to preparing variants of Mab 425 that are essentially not immunogenic or less immunogenic as compared with any their unmodified equivalent in using in vivo. The advantage of invention involves reducing immunogenicity of antibody.
EFFECT: improved and valuable properties of antibodies.
10 cl, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IDENTIFYING EPITOPES OF T-CELLS AND ITS USING IN PREPARING MOLECULES OF REDUCED IMMUNOGENICITY | 2002 |
|
RU2303264C2 |
| MODIFIED EPITOPES FOR AMPLIFYING RESPONSES OF CD4+ T-CELLS | 2013 |
|
RU2724994C2 |
| ARTIFICIAL PROTEINS WITH LOWERED ADJUVANTICITY | 2002 |
|
RU2363707C2 |
| COAGULATION FACTOR VIII WITH REDUCED IMMUNOGENICITY | 2013 |
|
RU2631801C2 |
| NEW IMMUNOGENIC PEPTIDES | 2015 |
|
RU2709711C2 |
| PREDICTION OF IMMUNOGENICITY OF T-CELL EPITOPES | 2014 |
|
RU2724370C2 |
| METHOD OF T-CELL EPITOP CHARTERING AND ELIMINATION | 2003 |
|
RU2334235C2 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| RA ANTIGEN PEPTIDES | 2004 |
|
RU2359974C2 |
| IMMUNOCONJUGATES FOR THE SPECIFIC INDUCTION OF T CELL CYTOTOXICITY AGAINST TARGET CELLS | 2016 |
|
RU2746021C2 |
